Navigation Links
Advinus Therapeutics, a TATA Enterprise, Meets Year 1 Milestone in Drug Discovery Alliance
Date:1/7/2014

PUNE, India, January 7, 2014 /PRNewswire/ --

Advinus Therapeutics Ltd., the TATA promoted Pharmaceutical R&D Company, announced today that it has received the first year milestone in its Research and Development Collaboration with Takeda Pharmaceutical Company Limited. The achievement of this milestone underscores the success of the collaboration and also provides validation of Advinus' capabilities in innovative Drug Discovery and Takeda's confidence in these capabilities. As a consequence, a payment of $ 3 M will be made by Takeda to Advinus to mark the achievement.

In October 2012, Advinus and Takeda announced a multi-year multi-project collaboration in the area of drug discovery. In this collaboration, Advinus is responsible for carrying out all the research required to identify candidate molecules for clinical development in several therapeutic areas while Takeda is responsible for the development and commercialization of these candidates.

"Achievement of the rather challenging first year milestone can be attributed to the truly collaborative nature of our relationship with Takeda as well as Advinus' young talent's ability to solve complex problems with efficiency and speed",  said Kasim Mookhtiar, CSO of Advinus.

About Advinus

Advinus Therapeutics is a research based Pharma Company founded by global Pharma executives and promoted by the TATA group. The company is the first of its kind in India to offer end to end development services to the global Pharma, Agro and Biotech industry while creating long term value through internal and collaborative Drug Discovery. The primary focus of the company's discovery efforts are in Metabolic Diseases, Inflammatory Diseases and Pain/ Neurodegeneration. Advinus also has an interest in pursuing the discovery of novel therapies for neglected or developing world diseases. Advinus' drug development operations supports and supplements the client resources at increased levels of cost-efficiency by providing services in the areas of Process Development, Drug Metabolism and Pharmacokinetics, Clinical Pharmacology, Safety Assessment, Formulation Development and Analytical R&D. For company information, visit Advinus at http://www.advinus.com.

Contact:
Advinus
Joshua Daniel
Corporate Communications
+91-80-66553104
http://www.advinus.com



'/>"/>
SOURCE Advinus Therapeutics Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
2. Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics
3. Boston Therapeutics, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
5. Dual Chamber Syringes & Injectors. Devices, Therapeutics, Markets and Forecasts
6. Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics
7. Inhibikase Therapeutics, Inc. Elects Anthony Zook To The Board Of Directors
8. Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
9. Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
10. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics, Inc.
11. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. 5, 2016 ... treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete ... better safety and tolerability profile of ropeginterferon alfa-2b versus HU ... and the ongoing long-term follow-up trial CONTINUATION-PV to obtain European ... intends to present this data to the FDA as it ...
(Date:12/4/2016)... Attorney General of Louisiana , Charles ... firm of Kahn Swick & Foti, LLC ("KSF"), announces that ... LCI ). On November 3, ... in Generic-Drug Probe to Be Filed by Year-End," which reported ... two years ago, now spans more than a dozen companies," ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi ... patients who do not do their research and undergo cosmetic dermatology treatments from unqualified ... midst of a renaissance and every other month a new treatment or device is ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with ... , Over the last 60 years, studies have shown that single electrode ...
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to gain ... of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser Resurfacing ... age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or textural ...
(Date:12/2/2016)... ... 02, 2016 , ... Lori G. Cohen and Sara K. ... at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference , ... of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health ...
Breaking Medicine News(10 mins):